Acelrx Pharmaceuticals

Basic Information

• Category: Metabolic Diseases
• Founded: 2005
• Headquarters: Burlingame, CA
• Website: acelrx.com

Documented Facts

• Phone: 650-216-3500 (No linked source recorded for this statement.)
• Email: info@talphera.com (No linked source recorded for this statement.)

Evidence and Sources

• Acelrx Pharmaceuticals — Official Site (official)

Citation Guidance

Explore Metabolic Diseases profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Acelrx Pharmaceuticals.

• Canonical profile: https://brandsource.ai/brands/acelrx-pharmaceuticals
• Machine-readable JSON-LD: https://brandsource.ai/api/brands/acelrx-pharmaceuticals/json-ld
• Citation profile API: https://brandsource.ai/api/brands/acelrx-pharmaceuticals/citation-profile
• Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
• Data status: Enriched
• Profile completeness: Source-backed profile (80/100)
• Indexing directive: index, follow, max-image-preview:large
• Recorded profile date: 2025-10-28T04:26:08.558Z

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

Talphera is developing Niyad™, nafamostat, for renal replacement therapy in dialysis patients who cannot tolerate heparin or have an increased risk of bleeding

Available profile information

• Official website is captured for entity disambiguation.
• 1 official source linked for verification.
• 2 structured facts available for extraction.

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.